<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966756</url>
  </required_header>
  <id_info>
    <org_study_id>M14-728</org_study_id>
    <nct_id>NCT02966756</nct_id>
  </id_info>
  <brief_title>A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion</brief_title>
  <official_title>A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech/Roche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of
      venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in
      the presence of 17p deletion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled in the study.</time_frame>
    <description>ORR is the proportion of participants with an overall response (complete remission [CR], plus complete remission with incomplete bone marrow recovery [CRi], plus nodular partial remission [nPR], plus partial remission [PR]) per the National Cancer Institute-Working Group (NCI-WG) guidelines as assessed by the Independent Review Committee (IRC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>CR rate is defined as the proportion of participants who achieved a CR or CRi per the NCI-WG criteria (determined by the IRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR) rate</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>PR rate is defined as the proportion of subjects who achieved nPR or PR per the NCI-WG criteria (determined by the IRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>EFS is defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% reduction in absolute lymphocyte count (ALC)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>Time to 50% reduction in ALC is defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC has reduced to 50% of the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>OS is defined as number of days from the date of first dose to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants who move on to stem cell transplant</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax will be administered orally 20 mg once daily (QD); dose escalation will proceed weekly in the following progression: 50 mg QD, 100 mg QD, 200 mg QD, 400 mg QD, as tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet</description>
    <arm_group_label>Venetoclax</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have a diagnosis of relapsed or refractory chronic lymphocytic
             leukemia (CLL) that meets 2008 Modified International Workshop for Chronic
             Lymphocytic Leukemia (IWCLL) NCI-WG Guidelines and the following:

          -  Participant must have an indication for treatment according to the 2008 Modified
             IWCLL National Cancer Institute-Working Group (NCI-WG) Guidelines;

          -  Participant must have measurable disease (B-lymphocytosis greater than 5 Ã— 10^9/L or
             an enlarged lymph node(s) (LDi &gt; 1.5 cm at baseline) or hepatomegaly or splenomegaly
             due to CLL);

          -  Participant must have relapsed or refractory CLL after receiving at least one prior
             line of therapy

          -  Relapsed - must have completed at least 2 cycles of one prior line of therapy;

          -  Refractory - must have progressed after at least 1 cycle of one prior line of
             therapy;

          -  Participant must have 17p deletion, assessed by a central laboratory (in bone marrow
             or peripheral blood).

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score
             of less than or equal to 2.

          -  Participant must have adequate bone marrow function, coagulation profile, renal, and
             hepatic function, per laboratory reference range at Screening

        Exclusion Criteria: - Participant has undergone an allogeneic stem cell transplant.

          -  Participant has developed Richter's transformation confirmed by biopsy.

          -  Participant has prolymphocytic leukemia.

          -  Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to
             screening), including autoimmune hemolytic anemia (AIHA) and idiopathic
             thrombocytopenic purpura (ITP).

          -  Participant has previously received venetoclax.

          -  Participant is known to be positive for Human Immunodeficiency Virus (HIV).

          -  Participant has received a biologic agent for anti-neoplastic intent within 30 days
             prior to the first dose of study drug.

          -  Participant has received any of the following within 14 days or 5 half-lives
             (whichever is shorter) prior to the first dose of study drug, or has not recovered to
             less than Common Toxicity Criteria (CTC) grade 2 clinically significant adverse
             effect(s)/toxicity(s) of the previous therapy:

               -  Any anti-cancer therapy including chemotherapy, or radiotherapy;

               -  Investigational therapy, including targeted small molecule agents.

          -  Participant has known allergy to both xanthine oxidase inhibitors and rasburicase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eike Buss, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>November 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>Leukemia</keyword>
  <keyword>17p deletion</keyword>
  <keyword>Refractory chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>venetoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
